Health Condition 1: F488- Other specified nonpsychotic mental disorders
Conditions
Interventions
Intervention1: Ma ‘jun Azaraqi: 3gm (semisolid) orally twice daily with water after meals for 28days
Control Intervention1: NIL: NIL
Sponsors
Central Council for Research in Unani Medicine CCRUM New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of either gender between 18 - 65 years of age will be included in this study.[4] 2. Patients of du ‘f al-asab (neurasthenia) will be included in this study as per the ICD-10 and CCMD- III diagnostic criteria: ICD-10 diagnostic criteria: (a). Presence of either persistent and distressing complaints of increased fatigue after mental efforts, or Persistent and distressing complaints of bodily weakness and exhaustion after minimal efforts (b). At-least two of the following: • Feeling of muscular aches and pains • Dizziness • Tension headache • Disturbed sleep • Inability to relax • Irritability • Dyspepsia CCMD- III diagnostic criteria: Presence of at-least three of five groups of following persistent symptoms: • Fatigue or weakness (physical or mental) • Irritability or worry • Excitability • Nervous pain • Sleep disorder
Exclusion criteria
Exclusion criteria: 1. Age below 18 and above 65 yrs 2. Patients having any primary psychiatric diseases including mood disorders, panic disorders and generalized anxiety disorders 3. Organic concurrent conditions like brain stroke and brain injury 4. Alcohol or drug addiction 5. Pregnancy and lactation 6. Agitation due to organic, toxic or iatrogenic causes 7. Patients having any systemic disease, chronic debilitating disease, T.B., Diabetes Mellitus, Hypertension, etc 8. Known case of carpal tunnel syndrome, herniated disc syndrome, peripheral nerve injury 9. Known cases of any neuromuscular abnormalities, neuromuscular junction disorders, myasthenia gravis, muscular disorders, diabetic neuropathy and autonomic neuropathies 10. Major medical illness under treatment 11. Patients with diseases requiring long term treatment 12. Use of any other alternative medication during the study period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The outcome will be measured by Clinical Global Impression (CGI) (7-point scale). In this scale, two types of observations such as severity of illness scale (CGI-S) (1: normal; 7: most severely illness), and improvement or change scale (CGI-I) (1: very much improved; 7: very much worsen) will be used.Timepoint: At baseline, 7th, 14th and 28th day. | — |
Secondary
| Measure | Time frame |
|---|---|
| Haematological & biochemical assessment for safety assessment i.e. CBC, LFT, KFT, Urine Routine & microscopic examination.Timepoint: At baseline and end of the treatment i.e. 28days | — |
Countries
India
Contacts
Public ContactDr Pradeep Kumar
Central Council for Research in Unani Medicine (CCRUM)
Outcome results
None listed